ATRA
Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.96
−2.40%Oct 14, 2026, 12:05 UTC
The U.S. Food and Drug Administration accepted Pierre Fabre Pharmaceuticals’ resubmitted Biologics License Application for tabelecleucel.
Source:Sep 30, 2026, 12:05 UTC
Pierre Fabre Pharmaceuticals resubmitted the tabelecleucel Biologics License Application to the U.S. Food and Drug Administration, as reported by partner Atara Biotherapeutics.
Source:Jun 12, 2026, 00:00 UTC
Atara Biotherapeutics appointed Brian Cherry as a Class I director and elected AnhCo Nguyen and Nachi Subramanian as directors, effective June 2026.